Hospach A, Rühlmann J M, Weller-Heinemann F
Zentrum für Pädiatrische Rheumatologie, Klinikum Stuttgart, Olgahospital, Kriegsbergstr. 62, 70174, Stuttgart, Deutschland.
Praxis für Kinderheilkunde und Jugendmedizin/Kinderrheumatologie, Göttingen, Deutschland.
Z Rheumatol. 2016 Apr;75(3):284-91. doi: 10.1007/s00393-016-0063-9.
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in infancy and childhood. Approximately 20 % of patients with JIA suffer from the polyarticular form of the disease, which causes a substantial disease burden and long-term sequelae. Therapeutic approaches have used steroids and conventional disease modifying antirheumatic drugs (DMARD) but over the last decade new drugs have become available for the treatment of JIA, in particular biologic DMARD. This article summarizes the current therapy options for polyarticular JIA.
幼年特发性关节炎(JIA)是婴幼儿及儿童时期最常见的风湿性疾病。约20%的JIA患者患有多关节型疾病,这会造成巨大的疾病负担和长期后遗症。治疗方法曾使用类固醇和传统的改善病情抗风湿药(DMARD),但在过去十年中,有了可用于治疗JIA的新药,尤其是生物DMARD。本文总结了多关节型JIA目前的治疗选择。